tbuckley/cabot-search huggingface dataset:
Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis
Authors: Narendranath Epperla, Kwang W. Ahn, Carlos Litovich, Sairah Ahmed, Minoo Battiwalla, Jonathon B. Cohen, Parastoo Dahi, Nosha Farhadfar, Umar Farooq, Cesar O. Freytes, Nilanjan Ghosh, Bradley Haverkos, Alex Herrera, Mark Hertzberg, Gerhard Hildebrandt, David Inwards, Mohamed A. Kharfan-Dabaja, Farhad Khimani, Hillard Lazarus, Aleksandr Lazaryan, Lazaros Lekakis, Hemant Murthy, Sunita Nathan, Taiga Nishihori, Attaphol Pawarode, Tim Prestidge, Praveen Ramakrishnan, Andrew R. Rezvani, Rizwan Romee, Nirav N. Shah, Ana Sureda, Timothy S. Fenske, Mehdi Hamadani
Journal: Journal of Hematology & Oncology (2019)

There is a paucity of data on the role of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with angioimmunoblastic T-cell lymphoma (AITL). Using the CIBMTR registry, we report here the outcomes of AITL patients undergoing an allo-HCT. We evaluated 249 adult AITL patients who received their first allo-HCT during 2000–2016. The median patient age was 56 years (range = 21–77). Majority of the patients were Caucasians (86%), with a male predominance (60%). Graft-versus-host disease (GVHD) prophylaxis was predominantly calcineurin inhibitor-based approaches while the most common graft source was peripheral blood (97%). Median follow-up of survivors was 49 months (range = 4–170 months). The cumulative incidence of grade 2–4 and grade 3–4 acute GVHD at day 180 were 36% (95% CI = 30–42) and 12 (95% CI = 8–17), respectively. The cumulative incidence of chronic GVHD at 1 year was 49% (95%CI 43–56). The 1-year non-relapse mortality (NRM) was 19% (95% CI = 14–24), while the 4-year relapse/progression, progression-free survival (PFS), and overall survival (OS) were 21% (95% CI = 16–27), 49% (95% CI = 42–56), and 56% (95% CI = 49–63), respectively. On multivariate analysis, chemoresistant status at the time of allo-HCT was associated with a significantly higher risk for therapy failure (inverse of PFS) (RR = 1.73 95% CI = 1.08–2.77), while KPS < 90% was associated with a significantly higher risk of mortality (inverse of OS) (RR = 3.46 95% CI = 1.75–6.87). Our analysis shows that allo-HCT provides durable disease control even in AITL patients who failed a prior auto-HCT and in those subjects with refractory disease at the time of allografting.
Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?
Authors: Remco J Molenaar, Tomas Radivoyevitch, Aaron T. Gerds, Aziz Nazha, Hetty E. Carraway, Anjali S. Advani, Matt Kalaycio, Navneet S. Majhail, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, Sudipto Mukherjee
Journal: Blood (2018)
AB1157 Clinical implications of ultrasonography (US) in monitoring disease activity of relapsing polychondritis (RP) and comparative investigation by us between auricle of rp, repeated trauma and healthy subject
Authors: S. Inotani, Y. Taniguchi, H. Nishikawa, E. Amano, S. Nakayama, Y. Terada
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Relapsing polychondritis (RP) is a rare systemic inflammatory disorder and might often be refractory. Therefore, the discovery of more convenient imaging modality than contrast-CT, MRI and FDG-PET/CT would be required on diagnosis and treatment. <h3>Objectives</h3> To assess the clinical implications of ultrasonography (US) in monitoring disease activity and diagnosis of relapsing polychondritis (RP). <h3>Methods</h3> Firstly, auricular chondritis of patients with RP (n=5) were assessed by US before and after treatments. Second, the relationship between US findings and other serum inflammatory markers were evaluated. Moreover, the comparisons of US findings between the auricle of patients with RP (n=5), repeated trauma (n=5) which is similar to auricle of RP, and healthy subjects (n=5) were also assessed. <h3>Results</h3> US finding before treatment showed low-echoic swollen auricular cartilage with increased power Doppler signals (PDS) in all cases of RP. US findings corresponded to biopsy findings. After treatment with prednisolone (PSL) combined with methotrexate, the swollen ear completely resolved. Then, US findings also showed dramatic reductions in swollen cartilage with the decrease in PDS. When serum inflammatory markers completely improved, but US finding remained in 1 of 5 cases, and this case showed flare due to PSL tapering. Finally, RP could be differentiated from the damage of repeated trauma with producing subperichondrial serous effusion. <h3>Conclusions</h3> US of auricular cartilage in RP possibly facilitates evaluation of auricular lesions and monitoring of disease activity, especially when we consider the treatment response and the timing of drug tapering. <h3>Disclosure of Interest</h3> None declared
FRI0111 Analysis of real-life infliximab and adalimumab data: drug switching and fate of antidrug antibodies and trough levels over time
Authors: D. Ho, S. Valtanen, M. Havana, L. Kröger, K. Eklund, T.S. Jokiranta
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Infliximab (IFX) and adalimumab (ADL) are biological drugs used in the treatment of rheumatoid arthritis (RA), spondyloarthropathy (SpA), and juvenile idiopathic arthritis (JIA). Development of antidrug antibodies (ADAb) may lead to increased drug clearance and loss of therapeutic drug trough levels (TL). Switching to another drug may be necessary after ADAb development. <h3>Objectives</h3> To use real-life data from a large Finnish rheumatology patient cohort to determine the association between drug switching and ADAbs and the fate of ADAbs and TLs after ADAb development. <h3>Methods</h3> Serum samples for IFX or ADL ADAb and TL measurements from 1345 (567 RA, 479 SpA, and 299 JIA) rheumatology patients were taken on a clinical basis in daily practice in 20 Finnish referral hospitals. ADAb analyses were performed at Sanquin laboratories (Amsterdam, The Netherlands) using radioimmunoassays; TL analyses were performed at United Medix Laboratories (Helsinki, Finland) using commercial methods (Promonitor ELISA, Progenika Biopharma). Samples were collected and analysed from January 2012 until September 2017. ADAb values≥12 AU/ml were considered positive; ADAb values were classified as low (12–30 AU/ml), intermediate (30–100 AU/ml) and high (≥100 AU/ml). <h3>Results</h3> On the basis of TL data, we identified 67 patients (5%) who switched drugs. Of these patients, 47 (70.2%) provided ADAb measurements for the first drug; 33 (49.3%) patients were ADAb positive. Most (22 patients, 63.6%) had high ADAbs. Forty-nine (73.1%) patients provided ADAb measurements for the second drug. Of these patients, 11 (16.4%) were ADAb positive against the second drug; seven (63.6%) had high ADAbs. We identified 48 (3.6%) ADAb-positive patients who provided at least one follow-up ADAb measurement. Of these patients, 32 (66.7%) experienced ADAb loss; most (24 patients, 50%) experienced complete ADAb loss (most recent ADAb value ≤12 AU/ml). Twenty-five patients that experienced ADAb loss had available TL measurements both before and after ADAb loss; 23 (92%) had increased TL after ADAb loss. Of the 16 patients that experienced ADAb gain, only 3/11 (27.3%) patients that had available TL measurements both before and after ADAb gain had increased TL after ADAb gain. <h3>Conclusions</h3> ADAb positivity is associated with drug switching; ADAb development against a second biologic drug is common. A significant proportion of ADAb-positive patients lose ADAbs over time. ADAb loss is associated with TL increase. <h3>Disclosure of Interest</h3> D. Ho Consultant for: Pfizer Oy, S. Valtanen: None declared, M. Havana: None declared, L. Kröger Consultant for: Roche, K. Eklund Grant/research support from: Pfizer, Speakers bureau: Abbvie, MSD, Pfizer, BMS, T. S. Jokiranta Grant/research support from: Pfizer, Consultant for: Abbvie, MSD, Pfizer, UCB
The Role of Antithrombin Lowering in Patients with Hemophilia: Hemostatic Control Pre- and Post-Fitusiran Dosing Interruption
Authors: Margaret V. Ragni, Pencho Georgiev, Michael Desmond Creagh, Toshko Jelev Lissitchkov, Steve K. Austin, Charles Richard Morris Hay, Inga Hegemann, Syed Rashid Saeed Kazmi, Pratima Chowdary, Savita Rangarajan, Meredith C. Foster, Qifeng Yu, Craig Benson, Kate Madigan, Huy Van Nguyen, Shariq Ali, Ketaki Kadam, Pallavi Jain, K. John Pasi
Journal: Blood (2018)
FRI0233 Does gout protect from parkinson’s disease: a case-control study from an urban population
Authors: C. Diaz-Torne, M.A. Pou, F. Orfila, S. Jeria, S. Fernandez, H. Park, I. Castellvi, H. Corominas
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> It has been demonstrated that hyperuricemia protects from Parkinson's disease (PD), but this relation is controversial in patients with gout. Inflammatory properties of urate monosodium(UMS) crystals deposition that appears when uric acid(UA) levels exceed its solubility faces antioxidant and neuroprotective features of soluble UA. Both, UMS crystals deposition and hyperuricemia coexist in gouty patients. There is several data that demonstrates that hyperuricemia protects from Parkinson's disease (PD). Results from different studies about the relation between them are controversial. Inflammatory properties of the urate crystals faces antioxidant and neuroprotective features of soluble UA. Both, UMS crystals and hyperuricemia coexist in gouty patients. <h3>Objectives</h3> To study if gout protects from Parkinson disease in a mediterranean urban population. <h3>Methods</h3> Primary care based matched case-control study. It has been carried out using the electronic clinical record database from the public health (Institut Català de la Salut) of the city of Barcelona. The database contains anonymous data from almost 1 million and a half people. Just people that were 40 years or older were studied. Were considered cases patients with a PD diagnose, or taking high specific anti-Parkinson's drugs (like l-dope, rasagiline, selegiline…), between 2006 and 2016. For every case we randomly selected four controls matched by gender and age. Data on risk factors was also collected for each individual (diabetes mellitus, hypertension, hypercholesterolemia and tobacco consumption before the PD diagnose), as well as age and gender. A multivariate logistic regression model was used to study the association of gout and PD adjusted by the presence of other risk factors. Adjusted Odds Ratios (aOR) and their 95% CI are provided. <h3>Results</h3> 21 789 persons with a PD diagnose and 87 156 controls were included. Mean age was 75.5 (SD 10.9) years. 55.6% were females. 2.5% of PD patients had a previous gout diagnose, compared to 4.8% of controls (p&lt;0.001). Multivariate Logistic regression model showed for gout: aOR=0.55 (0.50–0.61). Diabetes mellitus: aOR=1.18 (1.14–1.23); hypertension: aOR=0.7 (0.72–0.77); tobacco: aOR=0.55 (0.52–0.58); high cholesterol levels: aOR=0.60 (0.58–0.61). <h3>Conclusions</h3> Gout shows a protective effect on the development of Parkinson's disease, pointing that the antioxidant and neuro protective effect of UA seems to overcome its inflammatory properties in gouty patients. Gout shows a protective effect on the development of Parkinson's disease, pointing that the antioxidant and neuro protective effect of UA seems to overcome itsinflammatory properties in gouty patients. <h3>Disclosure of Interest</h3> None declared
Longitudinal High-Throughput T Cell Repertoire Profiling of Chronic Lymphocytic Leukemia Patients Under Different Types of Treatment: Implications for Combination Strategies
Authors: Anna Vardi, Elisavet Vlachonikola, Nikolaos Ioannou, Fotis Psomopoulos, Konstantia Kotta, Despoina Papazoglou, Maria Kotouza, Evangelia Koravou, Chrysi Galigalidou, Katerina Gemenetzi, Kostas Pasentsis, Michalis Iskas, Niki Stavroyianni, Achilles Anagnostopoulos, Alan G. Ramsay, Kostas Stamatopoulos, Anastasia Hadzidimitriou
Journal: Blood (2018)
OP0290-PARE Keep an eye out for invisible pains – a danish campaign
Authors: C.R. Ziegler
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> How does it feel to live with a RMD and have chronic pain? How do you explain pain caused by RMD to your friends and family? How do you make others understand how pain affects your daily life? The communication department of the Danish Rheumatism Association needed to convey living with invisible pains, because it is of such importance to people with RMDs. Based on interviews with the users (people with RMDs) we found the best way of making others understand was to create a film, which illustrated living with invisible pain. <h3>Objectives</h3> We wanted to increase the general understanding of RMDs and living with invisible pain in society. The secondary objective was to brand awareness of the Danish Rheumatism Association and to generate leads for further processing, e.g. signing up for membership. <h3>Methods</h3> Based on a few interviews with users and several posts from Social Media we focused on making invisible pain visible. By choosing the media of a film we could show what the users found difficult putting into words. The film had to be short to make it possible to share, e.g. on Facebook, and by choosing a film without speak we avoided language barriers. Through adverts we retargeted visitors to our website and generated more members of the association. <h3>Results</h3> We launched the film on World Arthritis Day 2017 In 3½ weeks the film reached 1 million users and more than 1000 comments on Facebook, and the number of followers went up by 2000. The total impact of the film will be presented in June 2018. <h3>Conclusions</h3> In the presentation we will show how and why the campaign could be such a success. We will focus on how to follow-up the positive results of generating leads and making invisible pain visible. <h3>Disclosure of Interest</h3> None declared
Brothers in Arms
Authors: Faith T. Fitzgerald
Journal: Annals of Internal Medicine (2019)

On Being a Doctor15 January 2019Brothers in ArmsFaith T. Fitzgerald, MDFaith T. Fitzgerald, MDUniversity of California, Davis, Sacramento, California (F.T.F.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-2331 Audio Reading - “Brothers in Arms” Audio. Virginia Hood, MD reads "Brothers in Arms," by F.T. Fitzgerald. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail When I was a resident at UCSF, we rotated every 4 months through three major allied teaching hospitals—Moffitt, San Francisco General, and Fort Miley VA. This rotation gave us a broader panoply of patients, their histories, and their problems that no single house of medicine could. The patients in VA hospitals in the early 1970s were principally veterans of World War II, the Korean conflict, and the Vietnam War.As the internal medicine resident, I was called to see a patient with abdominal pain admitted by the ER. He evidently was what was then (and is now?) called a “frequent ... Author, Article, and Disclosure InformationAffiliations: University of California, Davis, Sacramento, California (F.T.F.)Corresponding Author: Faith T. Fitzgerald, MD, UC Davis Medical Center, C/O Division of General Medicine, 4150 V Street, Suite 2400, Sacramento, CA 95817; e-mail, [email protected]edu. PreviousarticleNextarticle Advertisement Audio Reading - “Brothers in Arms” Audio. Virginia Hood, MD reads "Brothers in Arms," by F.T. Fitzgerald. Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics 15 January 2019Volume 170, Issue 2Page: 136KeywordsAbdominal painArmed forcesChildrenHistory of medicinePancreatic cancerPathologistsSurgeryTriageWalkingWeight loss ePublished: 15 January 2019 Issue Published: 15 January 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Detection of influenza A(H3N2) viruses exhibiting reduced susceptibility to the novel cap-dependent endonuclease inhibitor baloxavir in Japan, December 2018
Authors: Emi Takashita, Chiharu Kawakami, Hiroko Morita, Rie Ogawa, Seiichiro Fujisaki, Masayuki Shirakura, Hideka Miura, Kazuya Nakamura, Noriko Kishida, Tomoko Kuwahara, Keiko Mitamura, Takashi Abe, Masataka Ichikawa, Masahiko Yamazaki, Shinji Watanabe, Takato Odagiri
Journal: Eurosurveillance (2019)

The novel cap-dependent endonuclease inhibitor baloxavir marboxil was approved for the treatment of influenza virus infection in Japan in February 2018. Two influenza A(H3N2) viruses carrying an I38T substitution in the polymerase acidic subunit (PA) were detected in baloxavir-treated children in December 2018. This mutation is known to confer reduced susceptibility to baloxavir, and the two mutant viruses exhibited 76- and 120-fold reduced susceptibility to baloxavir.
Increasing Smoking Cessation in the United States
Authors: Scott J. Leischow
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0609 Clinical characteristics and outcome of spanish patients with acute myelitis associated with autoimmune diseases
Authors: A. González García, W.A. Sifuentes Giraldo, S. Sainz de la Maza, I. Barbolla Díaz, J. L, L. Manzano Espinosa
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Acute myelitis (AM) is a focal inflammatory disorder of the spinal cord characterised by motor, sensory, and autonomic dysfunctions that usually develop during a short period (several hours to days) and may resolve over several weeks to months. Acute has been reported as an unusual complication of autoimmune diseases (AD), mainly in systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). <h3>Objectives</h3> To analyse the frequency of concomitant AD in patients with patients with AM seen in a Spanish tertiary centre and to compare their clinical characteristics and outcome with those of AM patients without other AD. <h3>Methods</h3> We performed a retrospective study including all the patients diagnosed with AM in our centre between January 1989 and December 2017. Patients with previous history of spinal disease (multiple sclerosis [MS], compression, trauma, arteriovenous malformation, radiotherapy) and children were excluded. Demographics, clinical, laboratory, imagenology, therapeutic and outcome data were obtained from their medical records. <h3>Results</h3> During the study period 144 cases of AM were identified, 76 of them had complete data and were analysed. Most of the patient were women (47, 62%), with a mean age at diagnosis 42±17 years. The main causes of AM in our series were MS (35%), AD (18%), postviral myelitis (9%) and idiopathic (34%). The AD diagnosed in these patients were: SLE,<sup>4</sup> SS,<sup>3</sup> undifferentiated connective tissue disease,<sup>2</sup> Graves' disease,<sup>1</sup> ulcerative colitis,<sup>1</sup> polymyalgia rheumatic,<sup>1</sup> cryoglobulinemic vasculitis<sup>1</sup> and sarcoidosis.<sup>1</sup> A patient with MS had concomitantly another AD (inflammatory myopathy). Most of the patients with AD (12, 80%) were diagnosed of these disorders before the AM episode (median 48 months, range: 24–120). No differences regarding to sex, age and anatomical extension of AM were detected between AD and non-AD patients. The recurrence of AM was more frequent in non-AD patients (7% vs 54%, p&lt;0.001) and a tendency to less severe clinical course was found in AD patients (67% vs 41%, p=0.08). <h3>Conclusions</h3> AD were an important cause of AM in our series and this usually occurred after diagnose of AD, so it is important to consider AM when these patients develop neurological dysfunctions that suggest spinal cord damage. The outcome of AM seem to be better in patients with concomitant AD. <h3>Disclosure of Interest</h3> None declared
AB0545 Is lupus more prevalent in world’s most stressed countries?
Authors: A. Almathkouri, D. Pyne, A. Pakozdi, R. Rajkariar, A. Cove-smith, M. Lewis
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> A number of studies have implicated psychological stress as a trigger for autoimmune diseases. In a questionnaire study involving 120 lupus patients emotional stress was selected in over 75% cases as a trigger for their disease<sup>1</sup>. The role of stress as a trigger in lupus however is controversial. Here we study whether there is an association between the prevalence of lupus in various countries and their reported stress measures. <h3>Methods</h3> We undertook a literature review of the reported prevalence of lupus in various countries across the world. We then recorded the reported stress index in those countries from Bloomberg’s study<sup>2</sup>, which utilised seven equally weighted variables: homicide rates, GDP per capita income inequality, corruption perception, unemployment, urban air pollution and life expectancy to rank 74 countries according to stress levels. Pearsons correlation was used to measure association between national stress indices and lupus prevalence <h3>Results</h3> Results are presented in graph 1. Prevalence data was only available in the literature for limited countries. Of the countries studied no correlation was found between national stress indices and lupus prevalence (<b>r=−0.028 (p-value 0.449)</b> Conclusions: We found no association between a country’s prevalence of lupus and the measured stressfulness of its living environment. <h3>References</h3> [1] Stojanovich L. Stress as a trigger of autoimmune disease. Abstracts book: 5th International Congress on Autoimmunity, Sorrento, Italy, vol. 355. Autoimmun Rev; 2006. [2] United Nations Office on Drugs and Crime, International Monetary Fund, Central Intelligence Agency World Factbook, Transparency International, World Health Organization. May 2013. <h3>Disclosure of Interest</h3> None declared
Functional Status Is Associated with Outcomes after Allogeneic Stem Cell Transplantation for Older Patients with Hematologic Malignancies
Authors: Li-Wen Huang, Chiung-Yu Huang, Charalambos Andreadis, Aaron C. Logan, Gabriel N. Mannis, Catherine C. Smith, Karin M. Gaensler, Thomas G. Martin, Lloyd E. Damon, Michael A. Steinman, Rebecca L. Olin
Journal: Blood (2018)